Why is EDIT down?
Down 40% from Nov 9 to Nov 20 while the S&P 500 fell 8%.
- Editas Medicine fell 40% from Nov 9 to Nov 20 while biotech stocks fell a median 12%:
−3Long-term trend
Down 40% from Nov 9 to Nov 20 while the S&P 500 fell 8%.
−3Long-term trend
EDIT's Quality Score fell 1 point on Fri, Nov 20, to -8. Its market value fell under $300M ($264M).
Follow EDIT's trial news. Pro members can get an alert when Editas Medicine files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 70.5% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
Mon Nov 30: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.
After its last 4 reports it closed +7.5% on average, higher 4 of 4 times.
About 6 quarters
CEO Neil O'Neill Gilmore sold 21,164 shares on Nov 11, under a planned sale. 12 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
EDIT is #235 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 235 |
Share count against a year before: EDIT +70%, BEAM +2.1%, NTLA +27%.
Expected to report Mon Mar 8, before the open (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.15 a share, from $0.28.
“The increase was primarily attributable to revenue recognized in connection with clinical development milestones achieved by a strategic partner.”
EDIT's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily attributable to higher intellectual property and patent-related fees due to increased legal activity related to intellectual property defense.”
From its results filing (SEC filing · Nov 9)
Sales fell 15% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 8.7% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | +2.7% | +7.0% | -15.6% |
| Aug 5, 2026 | +2.5% | +5.5% | +3.3% |
| May 5, 2026 | +0.7% | +1.3% | +2.0% |
Sales grew in three of the last seven years, to $40.5M in 2025. It lost money in each of the eight years.
RSI 28.6, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: EDIT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
“The biotechnology and pharmaceutical industries, including in the gene therapy, gene editing and cell therapy fields, are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property and proprietary products.”
EDIT scores -8 today, which Breakaway calls Poor. It is #235 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 40% from Nov 9 to Nov 20 while the S&P 500 fell 8%. Cash lasts about 6 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
EDIT scores -8 today, which Breakaway calls Poor (below zero). That is #235 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind EDIT's -8.
Expected to report Mon Mar 8, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. EDIT closed higher after 4 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.